AbbVie says Phase 3 AFFIRM study shows subcutaneous Skyrizi beats placebo on Crohn’s remission, endoscopic response at week 12
ABBV•AbbVie said its Phase 3 AFFIRM study found subcutaneous Skyrizi produced better Crohn’s disease control than placebo, including remission and endoscopic response at week 12. Results and additional analyses are set for presentation at ACG 2026.
1. AFFIRM study results
AbbVie said patients receiving subcutaneous Skyrizi in the Phase 3 AFFIRM study achieved better disease control than those receiving placebo, with benefits holding through maintenance follow-up. Separate extension analyses scheduled for ACG 2026 indicate sustained long-term bowel healing in harder-to-treat patients. Real-world studies scheduled for the meeting also point to disease control with Rinvoq in advanced Crohn’s disease, including complex fistulizing cases.
